Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study

BACKGROUND: There is limited information regarding disease-modifying antirheumatic drug (DMARD)-dependent risks of overall, incident, and recurrent herpes zoster (HZ) during first-line biologic DMARD (bDMARD) or targeted synthetic DMARD (tsDMARD) treatment among patients with seropositive rheumatoid...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Seogsong, Choi, Seulggie, Park, Sang Min, Kim, Jinseok, Ghang, Byeongzu, Lee, Eun Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330646/
https://www.ncbi.nlm.nih.gov/pubmed/35902964
http://dx.doi.org/10.1186/s13075-022-02871-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330646/
https://www.ncbi.nlm.nih.gov/pubmed/35902964
http://dx.doi.org/10.1186/s13075-022-02871-1

Ejemplares similares